New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma
Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2023-07-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839584313463537664 |
|---|---|
| author | M. А. Sorokina A. V. Rakhteenko T. R. Grishina |
| author_facet | M. А. Sorokina A. V. Rakhteenko T. R. Grishina |
| author_sort | M. А. Sorokina |
| collection | DOAJ |
| description | Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory and recurrent PTCL who do not respond to such therapy or demonstrate adverse events, which makes it important to personalize therapy and search for predictive markers, followed by thorough analytical and clinical validation. The literature highlights the importance of using biomarkers obtained from whole exome sequencing and tumor transcriptome sequencing. The review discusses the T cell ontogenesis, as well as the possibilities of personalization of anticancer drugs such as azacitidine, duvelisib, romidepsin, and bortezomib for the treatment of refractory or recurrent PTCL. |
| format | Article |
| id | doaj-art-5a0887d944a34f6ea4c3e01ab3e566a0 |
| institution | Matheson Library |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2023-07-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-5a0887d944a34f6ea4c3e01ab3e566a02025-08-03T19:49:36ZrusIRBIS LLCФармакоэкономика2070-49092070-49332023-07-0116229130210.17749/2070-4909/farmakoekonomika.2023.170428New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphomaM. А. Sorokina0A. V. Rakhteenko1T. R. Grishina2Ivanovo State Medical Academy; Pirogov Russian National Research Medical UniversityDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyIvanovo State Medical AcademyToday, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory and recurrent PTCL who do not respond to such therapy or demonstrate adverse events, which makes it important to personalize therapy and search for predictive markers, followed by thorough analytical and clinical validation. The literature highlights the importance of using biomarkers obtained from whole exome sequencing and tumor transcriptome sequencing. The review discusses the T cell ontogenesis, as well as the possibilities of personalization of anticancer drugs such as azacitidine, duvelisib, romidepsin, and bortezomib for the treatment of refractory or recurrent PTCL.https://www.pharmacoeconomics.ru/jour/article/view/807peripheral t cell lymphomaazacitidineduvelisibromidepsinbortezomibbiomarkerspersonalized medicine |
| spellingShingle | M. А. Sorokina A. V. Rakhteenko T. R. Grishina New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma Фармакоэкономика peripheral t cell lymphoma azacitidine duvelisib romidepsin bortezomib biomarkers personalized medicine |
| title | New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma |
| title_full | New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma |
| title_fullStr | New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma |
| title_full_unstemmed | New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma |
| title_short | New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma |
| title_sort | new pharmacotherapeutic approaches for the treatment of peripheral t cell lymphoma |
| topic | peripheral t cell lymphoma azacitidine duvelisib romidepsin bortezomib biomarkers personalized medicine |
| url | https://www.pharmacoeconomics.ru/jour/article/view/807 |
| work_keys_str_mv | AT masorokina newpharmacotherapeuticapproachesforthetreatmentofperipheraltcelllymphoma AT avrakhteenko newpharmacotherapeuticapproachesforthetreatmentofperipheraltcelllymphoma AT trgrishina newpharmacotherapeuticapproachesforthetreatmentofperipheraltcelllymphoma |